{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:15:32Z","timestamp":1788491732378,"version":"build-2803163510"},"reference-count":24,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,1,28]]},"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the perceptions and experiences of people with specific immune-mediated inflammatory diseases during the process of switching from Humira to biosimilar adalimumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cross-sectional survey.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>An anonymised, self-administered, web-based survey.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>The participants were drawn from members and non-members of either the National Rheumatoid Arthritis Society, the National Axial Spondyloarthritis Society, Crohn\u2019s and Colitis UK, or Psoriasis Association. Birdshot Uveitis Society and Olivia\u2019s Vision also signposted to the survey links.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 899 people living with various immune mediated inflammatory diseases participated in this survey. Thirty-four per cent of respondents reported poor overall satisfaction with their biosimilar adalimumab after the switch, associated with complaints related to the switching process including lack of shared decision making, scarcity of information provided by or signposted to by the department instigating the switch as well as lack of training with the new injection device. Where training with the new device had been provided, there were significantly reduced reports of pain when injecting the new biosimilar (OR 0.20, 95% CI 0.07 to 0.55), side effects (OR 0.17, 95% CI 0.06 to 0.47) and difficulty in using the new injection device (OR 0.25, 95% CI 0.15 to 0.41). Self-reported side effects were reduced by (OR 0.13, 95% CI 0.05 to 0.38) when written information was provided by healthcare professionals and by (OR 0.15, 95% CI 0.05 to 0.42) with provision of verbal information. Difficulty in using the new injection device was also reduced by provision of satisfactory information such as written documents (OR 0.38, 95% CI 0.23 to 0.63) or by verbal communication with healthcare professionals (OR 0.45, 95% CI 0.27 to 0.73). Finally, provision of satisfactory written or verbal information was associated with a reduction in any negative perception regarding symptom control with the new biosimilar by (OR 0.05, 95% CI 0.004 to 0.57) and by (OR 0.15, 95% CI 0.03 to 0.84), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patient reported experiences of the process of switching from originator to biosimilar emphasise the importance of clear communication, training and information in order to optimise perception and maximise achievable outcomes with the new treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-050949","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T11:21:45Z","timestamp":1645010505000},"page":"e050949","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients\u2019 satisfaction: a cross-sectional survey by patient organisations"],"prefix":"10.1136","volume":"12","author":[{"given":"Kayoko","family":"Kaneko","sequence":"first","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3950-6346","authenticated-orcid":false,"given":"Daniel","family":"Prieto-Alhambra","sequence":"additional","affiliation":[{"name":"Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Jacklin","sequence":"additional","affiliation":[{"name":"National Rheumatoid Arthritis Society (NRAS), Maidenhead, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailsa","family":"Bosworth","sequence":"additional","affiliation":[{"name":"National Rheumatoid Arthritis Society (NRAS), Maidenhead, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Dickinson","sequence":"additional","affiliation":[{"name":"National Axial Spondyloarthritis Society, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Berry","sequence":"additional","affiliation":[{"name":"Crohn\u2019s & Colitis, Hatfield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McAteer","sequence":"additional","affiliation":[{"name":"Psoriasis Association, Northampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-6167","authenticated-orcid":false,"given":"Peter C","family":"Taylor","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"key":"2025121400152581000_12.2.e050949.1","unstructured":"Robinson J . The pharmaceutical Journal. Available: https:\/\/pharmaceutical-journal.com\/ article\/feature\/preparing-for-the-big-biologic-switch"},{"key":"2025121400152581000_12.2.e050949.2","unstructured":"Medicines Diagnostics and Personalised Medicine Policy Team, National Medical Directorate, NHS England . Commissioning framework for biological medicines (including biosimilar medicines), 2017. Available: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2017\/09\/biosimilar-medicines-commissioning-framework.pdf [Accessed 29 Apr 2020]."},{"key":"2025121400152581000_12.2.e050949.3","unstructured":"Medicines and Diagnostics Policy Unit, NHS England . Commissioning intentions: adalimumab, 2018. Available: https:\/\/www.sps.nhs.uk\/wp-content\/uploads\/2018\/09\/20180925-Contractual-Commissioning-Intentions-Adalimumab_corporate-template.pdf [Accessed 29 Apr 2020]."},{"key":"2025121400152581000_12.2.e050949.4","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40259-017-0244-3","article-title":"Perception of Originator biologics and biosimilars: a survey among Belgian rheumatoid arthritis patients and rheumatologists","volume":"31","author":"van Overbeeke","year":"2017","journal-title":"BioDrugs"},{"key":"2025121400152581000_12.2.e050949.5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40259-017-0238-1","article-title":"Patients' understanding and attitudes towards infliximab and etanercept biosimilars: result of a UK web-based survey","volume":"31","author":"Aladul","year":"2017","journal-title":"BioDrugs"},{"key":"2025121400152581000_12.2.e050949.6","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/art.40388","article-title":"The science behind biosimilars: entering a new era of biologic therapy","volume":"70","author":"Bridges","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025121400152581000_12.2.e050949.7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2147\/PPA.S238843","article-title":"Real-World Patient Experience of Switching Biologic Treatment in Inflammatory Arthritis and Ulcerative Colitis - A Systematic Literature Review","volume":"14","author":"Luttropp","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"2025121400152581000_12.2.e050949.8","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1007\/s10067-019-04679-y","article-title":"Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis","volume":"38","author":"Edwards","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2025121400152581000_12.2.e050949.9","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1080\/14712598.2019.1645114","article-title":"Long-Term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3B extension study (VOLTAIRE-RAext)","volume":"19","author":"Cohen","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"2025121400152581000_12.2.e050949.10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13075-019-1857-3","article-title":"An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis","volume":"21","author":"Cohen","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025121400152581000_12.2.e050949.11","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/art.40444","article-title":"Switching from reference adalimumab to SB5 (adalimumab Biosimilar) in patients with rheumatoid arthritis: Fifty-Two-Week phase III randomized study results","volume":"70","author":"Weinblatt","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025121400152581000_12.2.e050949.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212245"},{"key":"2025121400152581000_12.2.e050949.13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13075-018-1676-y","article-title":"A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira\u00ae) in the treatment of active rheumatoid arthritis","volume":"20","author":"Fleischmann","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025121400152581000_12.2.e050949.14","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jbspin.2018.09.007","article-title":"Switch to a biosimilar: whatever the cost?","volume":"85","author":"Sigaux","year":"2018","journal-title":"Joint Bone Spine"},{"key":"2025121400152581000_12.2.e050949.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30068-5"},{"key":"2025121400152581000_12.2.e050949.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.11.015"},{"key":"2025121400152581000_12.2.e050949.17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh587"},{"key":"2025121400152581000_12.2.e050949.18","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00228-018-2418-4","article-title":"The nocebo effect challenges the non-medical infliximab switch in practice","volume":"74","author":"Boone","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"2025121400152581000_12.2.e050949.19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40744-019-00190-7","article-title":"Nonmedical switching from originators to biosimilars: does the nocebo effect explain treatment failures and adverse events in rheumatology and gastroenterology?","volume":"7","author":"Fleischmann","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2025121400152581000_12.2.e050949.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214374"},{"key":"2025121400152581000_12.2.e050949.21","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41584-018-0110-9","article-title":"Nocebos in rheumatology: emerging concepts and their implications for clinical practice","volume":"14","author":"Kravvariti","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2025121400152581000_12.2.e050949.22","unstructured":"National Institute for Health and Care Excellence . Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. Technology appraisal guidance (TA375) 26 January 2016. Available: https:\/\/www.nice.org.uk\/guidance\/ta375\/chapter\/1-Recommendations"},{"key":"2025121400152581000_12.2.e050949.23","unstructured":"Infliximab and adalimumab for the treatment of Crohn\u2019s disease. Technology appraisal guidance [TA187]. Available: https:\/\/www.nice.org.uk\/guidance\/ta187 [Accessed 19 May 2010]."},{"key":"2025121400152581000_12.2.e050949.24","unstructured":"Adalimumab for the treatment of adults with psoriasis. Technology appraisal guidance [TA146], 2008. Available: https:\/\/www.nice.org.uk\/guidance\/ta146\/chapter\/1-Guidance"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-050949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T08:15:34Z","timestamp":1765700134000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-050949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,16]]},"published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1136\/bmjopen-2021-050949"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-050949","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}